Article Figures & Data
Figures
Tables
Data Supplement
- Supplemental Data -
Supplementary Table 1 - Basic Equations, FDA (2017), Used in the Initial Assessment of the Risk of Nemiralisib Perpetrating DDIs.
Supplementary Table 2 - Static Mechanistic Equations, (Shardlow, 2011), Used in the Second Tier for the Assessment of Risk of Nemiralisib Perpetrating DDIs.
Supplementary Table 3 - Reversible and metabolism-dependent inhibition: incubation conditions.
Supplementary Table 4 - MS/MS conditions for CYP reversible and MDI inhibition.
Supplementary Table 5 - MDI kinetics: incubation conditions.
Supplementary Table 6 - Drug transporter inhibition: experimental conditions.
Supplementary Table 7 - Vilanterol model parameters.
Supplementary Table 8 - Nemiralisib model parameters.
Supplementary Table 9 - In-vitro transporter data.
Supplementary Table 10 - Itraconazole and hydroxy-itraconazole PK parameters on Day 1 and Day 5 following 10 days repeat daily oral itraconazole.
Supplementary Table 11 - Simulated and observed exposure for Inhaled Vilanterol (CYP3A4 substrate).
Supplementary Table 12 - Simulated and observed drug interaction with Inhaled Vilanterol and Ketoconazole.
Supplementary Table 13 - Nemiralisib simulated and observed pharmacokinetics after single-dose intravenous, oral and inhaled administration.
Supplementary Figure 1 - Sensitivity analysis to assess the impact of nemiralisib dose on the exposure of midazolam.
Supplementary References
- Supplemental Data -